BRISBANE, Calif., March 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced that it will hold a webcast of a live conference call today at 5:00 p.m. EST to discuss the outcome of today’s Pulmonary-Allergy Drugs Advisory Committee (PADAC). The committee was convened by the U.S. Food and Drug Administration to review and discuss the company’s New Drug Application (NDA) for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
